Roger Johnson, MD
Pulmonary Disease · Evansville, INNPI 1780624742
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Genentech USA, Inc. at 36.0% of the total. Reporting peaked in 2019 at $20,691 and has fallen 99.0% since, to $215 in 2025. Among pulmonary disease clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $238.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$10K
- Bayer$9K
- Intuitive Surgical$4K
- AstraZeneca$1K
- Bard Access Systems, Inc.$850
- Pulmonx Corporation$563
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$15,85060%
- Travel & lodging$4,90619%
- Food & beverage$2,59510%
- Education$3,04411%
- Gifts$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 14 | $9,542 |
| Bayer | 9 | $8,521 |
| Intuitive Surgical | 8 | $4,031 |
| AstraZeneca | 12 | $1,291 |
| Bard Access Systems, Inc. | 8 | $850 |
| Pulmonx Corporation | 9 | $563 |
| Johnson & Johnson | 2 | $555 |
| Pinnacle Biologics, Inc | 5 | $196 |
| Insmed, Inc. | 6 | $174 |
| GSK | 7 | $166 |
| La Jolla Pharmaceutical Company | 2 | $151 |
| Auris Health, Inc. | 1 | $104 |
| Sunovion Pharmaceuticals Inc. | 9 | $91 |
| Boehringer Ingelheim | 5 | $67 |
| Merck | 3 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $27 |
| Actelion Pharmaceuticals US, Inc. | 1 | $25 |
| Circassia Inc. | 2 | $23 |
| Grifols USA, LLC | 1 | $20 |
| United Therapeutics Corporation | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $15 |
| Verona Pharma, Inc. | 1 | $14 |
| Pfizer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Esbriet$9,397
- Adempas$8,370
- Da Vinci Surgical System$3,764
- SYMBICORT$1,000
- CFN PLEURX$744
- MONARCH$660
- Arikayce$150
- ZEPHYR DELIVERY CATHETER$137
- ZEPHYR ENDOBRONCHIAL VALVE$137
- PULMONX CHARTIS TABLET CONSOLE$137
- CHARTIS CATHETER$137
- GIAPREZA$117
- TRELEGY ELLIPTA$110
How this compares
$26,516 in reported general payments places this provider in the 90th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tyvaso DpiTreprostinil | 12 | $308,341 |
| AdempasRiociguat | 20 | $266,475 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 171 | $148,088 |
| Breo ElliptaFluticasone/Vilanterol | 145 | $66,386 |
| Ambrisentan | 35 | $63,727 |
| Dupixent PenDupilumab | 12 | $52,850 |
| Spiriva RespimatTiotropium Bromide | 39 | $35,182 |
| SymbicortBudesonide/Formoterol Fumarate | 84 | $25,149 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $14,877 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $14,000 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $12,398 |
| Arnuity ElliptaFluticasone Furoate | 28 | $11,871 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $6,051 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 11 | $4,399 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $8,521 | $266,47520 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $166 | $243,054373 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,291 | $40,026104 claims |
| Boehringer IngelheimSpiriva Respimat | $67 | $35,18239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Evansville
- Victor ChavezEvansville$52K
- Raghav GuptaEvansville$10K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
- Ajay DeshpandeTerre Haute$304K
- Faisal KhanGreenwood$207K
- Sandeep KukrejaGreenwood$206K
- Raja DevanathanHobart$193K
- Asaad JandaliMunster$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.